Pfizer (NYSE:PFE) Trading 0% Higher - What's Next?

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) rose 0% on Tuesday . The company traded as high as $25.74 and last traded at $25.54. Approximately 13,407,105 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 37,195,734 shares. The stock had previously closed at $25.53.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent research reports. StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Wolfe Research initiated coverage on shares of Pfizer in a report on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price for the company. Guggenheim reissued a "buy" rating and issued a $33.00 target price on shares of Pfizer in a report on Monday, February 10th. Finally, Evercore ISI raised shares of Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Price Performance

The stock has a market capitalization of $149.14 billion, a PE ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock's 50 day moving average price is $26.28 and its 200-day moving average price is $27.44.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This is an increase from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer's payout ratio is presently 121.99%.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pfizer

Several hedge funds have recently modified their holdings of the stock. PVG Asset Management Corp acquired a new position in shares of Pfizer during the 4th quarter worth approximately $673,000. Vermillion Wealth Management Inc. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $64,000. Forum Financial Management LP raised its stake in shares of Pfizer by 56.8% during the 4th quarter. Forum Financial Management LP now owns 96,645 shares of the biopharmaceutical company's stock worth $2,564,000 after buying an additional 35,001 shares during the period. Griffith & Werner Inc. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $2,730,000. Finally, Jupiter Wealth Management LLC raised its stake in shares of Pfizer by 5.9% during the 4th quarter. Jupiter Wealth Management LLC now owns 71,750 shares of the biopharmaceutical company's stock worth $1,904,000 after buying an additional 4,000 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.